From Breakingviews: AstraZeneca's deal with Oxford researchers to produce and distribute the latter’s potential COVID-19 vaccine is encouraging
George Washington is seen with printed medical mask on the one dollar banknote in this illustration taken, March 31, 2020. REUTERS/Dado Ruvic/IllustrationREALITY STARTS SETTING IN FOR EARNINGS. Around half the S&P 500 Index constituents have reported first-quarter earnings, including the start of the sharp downturn triggered by the coronavirus. Profit for the group in the period is set to drop nearly 15%, according to Refinitiv data.
IN IT TO WIN IT? AstraZeneca has struck a deal with Oxford University researchers to produce and distribute the latter’s potential Covid-19 vaccine. The treatment, developed by the Jenner Institute and Oxford Vaccine Group, is already being tested in England. Chief Executive Pascal Soriot reckons the Anglo-Swedish drugmaker could produce 100 million doses by year end.
Goldman has had bigger say-on-pay thwacks, as have peers. In 2016 its pay proposals garnered just 66% support. While Bank of America has polled above 90% since the financial crisis, Citigroup lost its non-binding vote as recently as 2012. JPMorgan, whose boss Jamie Dimon is the best paid of all, got just 72% support last year, leading it to tweak its incentives.
Revenue rose only 3%, though, a challenge for Twitter even before Covid-19 snapped shut wallets. It’s an opportunity, too, though: Dorsey, fresh from a fight with activist investor Elliott Management, needs to focus on the “m” in mDAU.
Canada Latest News, Canada Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Corona Capital: Tepid earnings, red-hot bondsConcise views on the pandemic’s corporate and financial fallout. Halfway through earnings season, things are going from mediocre to bad at big U.S. companies. Meanwhile, Boeing’s $25 billion bond issue shows the Fed has cast a spell on the corporate debt market.
Read more »
Breakingviews - Corona Capital: Fed, GE, Ford, AstraZenecaThere are crumbs of comfort for VW and Daimler, and electric-car maker BYD is making lemonade out of lemons. Plus: Chris Hohn at TCI’s take on how to be an activist. Catch up with the latest pandemic-related insights from Breakingviews here:
Read more »
Corona what? Tesla retail investors appear unfazed by virus impactWhen Tesla Inc reports first-quarter results after the bell on Wednesday, many individual shareholders will not be looking for details on the subject that drives most conversations: the effect of the novel coronavirus pandemic.
Read more »
Corona Capital: Tepid earnings, red-hot bondsConcise views on the pandemic’s corporate and financial fallout. Halfway through earnings season, things are going from mediocre to bad at big U.S. companies. Meanwhile, Boeing’s $25 billion bond issue shows the Fed has cast a spell on the corporate debt market.
Read more »
Breakingviews - Corona Capital: Fed, GE, Ford, AstraZenecaThere are crumbs of comfort for VW and Daimler, and electric-car maker BYD is making lemonade out of lemons. Plus: Chris Hohn at TCI’s take on how to be an activist. Catch up with the latest pandemic-related insights from Breakingviews here:
Read more »